FDA Guides Safe Gene Editing Tests for Human Therapies
Published Date: 4/15/2026
Notice
Summary
The FDA just dropped a draft guide to help companies safely test gene editing in human therapies using super-smart DNA sequencing. If you’re making or studying these gene therapies, this guide shows how to check for safety before starting human trials. Comments on the draft are open until July 14, 2026, so get your thoughts in early to shape the final rules—this could speed up safe, cutting-edge treatments and impact development costs.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
NGS Safety Testing Guidance for Gene Therapies
If you develop human gene‑editing therapies, FDA published a draft guidance (Federal Register April 15, 2026) that recommends next‑generation sequencing (NGS) methods for nonclinical studies likely needed to support Investigational New Drug applications (INDs) and Biologics License Applications (BLAs). The draft focuses on checking for off‑target editing and loss of genome integrity in investigational genome editing products.
Opportunity to Comment by July 14, 2026
FDA is accepting comments on the draft guidance through July 14, 2026. You can submit comments electronically at https://www.regulations.gov (Docket No. FDA-2026-D-1255) or send written/paper comments to the Dockets Management Staff at the Rockville, MD address listed in the notice.
Guidance Is Draft and Not Binding
The draft guidance represents FDA's current thinking but is not binding and does not establish rights. You may use an alternative approach if it satisfies applicable statutes and regulations.
No New Information Collections; OMB Numbers Listed
The draft guidance contains no new collections of information under the Paperwork Reduction Act but refers to previously approved collections: OMB control number 0910-0014 (IND submissions, 21 CFR part 312), 0910-0338 (BLA submissions, 21 CFR part 601), and 0910-0543 (human gene therapy products, 21 CFR part 1271).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07283 — 735th Meeting of the Advisory Committee on Reactor Safeguards (ACRS)
The Advisory Committee on Reactor Safeguards (ACRS) is meeting May 6-8, 2026, to focus on new rules for tiny nuclear reactors and changes from a recent executive order that trims their workload. This means fewer reviews, zooming in only on big, important issues, which could speed up licensing and save money. The public can join online, making it easy for everyone to stay in the loop about nuclear safety updates.
Next: 2026-07287 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of Currently Approved Collection
The Department of Justice’s Office on Violence Against Women is asking for 30 more days of public comments to extend a form that helps track progress in campus safety programs. This extension won’t add new costs but keeps the current info collection going smoothly. If you’re involved in campus safety or grant programs, your feedback by May 15, 2026, really counts!